{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP05054",
    "Peptide Name": "Ctn[15-34] (Ctn15-34, Synthetic AMPs, C-terminal fragment of crotalicidin, Lys-rich, XXA, UCLL1c)",
    "Source": "sequence truncation, snake cathelicidin analog, animal-derived, natural derivatives",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "KKRLKKIFKKPMVIGVTIPF",
    "Sequence Length": 20,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Synergistic AMPs",
      "Anticancer"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 8,
    "Boman Index": 0.68,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "45%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is 58.82% similar toCrotalicidinK: 50%, F: 21%, V: 14%.Activity: active against Gram+ E. faecalis ATCC 29212 and a clinical isolate (MIC 54 uM), S. aureus ATCC 29213 and a clinical isolate (MIC 54 uM), S. pyogenes clinical isolate (MIC 3.4 uM), Gram- P. aeruginosa ATCC 27853 and a clinical isolate (MIC 27 uM), K. pneumoniae clinical isolate (MIC 3.4 uM), E. coli ATCC 25922 and a clinical isolate (MIC 0.11-3.4 uM), and A. baumannii clinical isolate (MIC 1.7 uM).Fungi: active against yeasts C. parapsilosis ATCC 22019 (MIC 40 uM), C. krusei ATCC 6258 (MIC 5 uM),  C. tropicalis LABMIC 0109 (MIC 5-10 uM), C. albicans LABMIC 0107 or 0108 (MIC 10 uM), C. parapsilosis LABMIC 0113 (MIC 5 uM), C. laurentii LABMIC 0404 (MIC 5 uM), Dermatophythes M-canis LABMIC 0401 (MIC >40 uM), T-rubrum LABMIC 0203 or 0204 (MIC > 40 uM)  (Cavalcante et al., 2017).SAR: Like human cathelicidin LL-37, C-terminal fragment contains the major antimicrobial region against Gram- pathogens.In vitro toxicity: human RBC: HC50 > 100 uM, less hemo.lytic.AMP stability:serum:human: half-life 770 min (50% serum).Synergy:drug:  it showed synergistic antifungal activity with amphotericin B (FICI 0.26) (Cavalcante et al., 2017).",
    "Author": "Falcao CB, Pérez-Peinado C, de la Torre BG, Mayol X, Zamora-Carreras H, Jiménez MÁ, Rádis-Baptista G, Andreu D. 2015",
    "Reference": "J Med Chem. 2015 Nov 12;58(21):8553-63. doi: 10.1021/acs.jmedchem.5b01142.PubMed",
    "Title": "Structural Dissection of Crotalicidin, a Rattlesnake Venom Cathelicidin, Retrieves a Fragment with Antimicrobial and Antitumor Activity."
  },
  "3D Structure": []
}